신경기술 시장 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the neurotechnology market size is expected to grow from USD 15.77 billion in 2025 to USD 17.84 billion in 2026 and is forecast to reach USD 33.05 billion by 2031 at 13.12% CAGR over 2026-2031.

This report is Segmented by Product (Neurostimulation Devices, Brain-Computer Interfaces, Neuro-Prosthetics, Other Products), Application (Parkinson's Disease, Epilepsy, Alzheimer's and Dementia, Chronic Pain Management, and More), End User (Hospitals, Specialty Clinics, Home-Care Settings and More), and Geography (North America, Europe, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Neurotechnology Market Trends and Insights

Rising Prevalence of Neurological Disorders

The global burden of neurodegenerative diseases has surpassed 50 million cases and continues to climb in tandem with aging populations. In the United States alone, Parkinson's disease affects 5%-10% of the geriatric population each year, with roughly 500,000 new diagnoses annually. Health-system planners are moving capital toward early-intervention devices that can slow functional decline and lessen long-term care costs. This demographic reality underpins aggressive investment in early-stage brain-monitoring platforms positioned for future preventive protocols.

Surging Advancements in Neuroscience and Technology

Breakthroughs in microscale electrode arrays now allow sensors to sit between hair follicles while maintaining 96.4% signal-detection accuracy over prolonged use. Parallel gains in large-language-model-powered decoding have yielded prototypes capable of translating cortical signals into coherent speech. These innovations are widening the neurotechnology market by creating hybrid product classes that straddle consumer wearables and regulated medical devices.

High Up-front Device & Procedure Costs Limiting Adoption Beyond Tier-1 Hospitals

Advanced neuromodulation platforms may cost more than USD 100,000, with implantable components adding USD 20,000-50,000 per patient. This expenditure confines deployments to academic centers and limits penetration in community settings. Insurance coverage is uneven, amplifying out-of-pocket burdens and dampening uptake in resource-constrained markets. Manufacturers are piloting risk-sharing and outcomes-based contracts, but these frameworks remain in formative stages.

Other drivers and restraints analyzed in the detailed report include:

1. Growing Demand for Improved Treatment Options
2. Rising Public & Private Funding for Neurotechnology R&D and Commercialization
3. Complex, Multiregional Regulatory Approvals Delaying Market Entry

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

North America generated 39.10% of global revenue in 2025 on the strength of a mature clinical infrastructure, active venture capital, and an accelerating FDA Breakthrough Devices program. Approvals such as the world's first adaptive deep-brain stimulation system for Parkinson's patients illustrate regulators' willingness to fast-track transformative solutions. Strategic alliances linking hospital systems with technology firms are proliferating, enabling rapid validation of neural-data-driven digital therapeutics.

Asia-Pacific is the neurotechnology market's fastest-growing region at a 14.94% CAGR through 2031. China's national BCI strategy has catalyzed cross-sector consortia that pair academic labs with semiconductor manufacturers, resulting in real-time decoding of Chinese speech at sub-100-millisecond latency. Government funding, manufacturing agility, and large domestic patient pools are shortening product-development cycles. Parallel innovation in Japan and South Korea, leveraging sensor miniaturization expertise, is producing export-ready non-invasive neuro-monitoring devices.

Europe maintains stringent regulatory oversight, but its emphasis on long-term safety data has fostered pioneering neuromodulation protocols for movement disorders. The United Kingdom's National Health Service is trialing an ultrasound-enabled BCI for mood modulation under an USD 8 million value-based framework. National reimbursement agencies are actively evaluating cost-effectiveness models that could unlock broader adoption once outcome thresholds are met.

Geography Analysis

Neuro-stimulation devices held 45.21% of the neurotechnology market in 2025, validating decades of clinical experience and established reimbursement. Adoption continues to rise as adaptive algorithms refine stimulation parameters in real time, reducing habituation and side-effects. Medtronic's Inceptiv system senses bodily responses 50 times per second to maintain therapeutic thresholds. This convergence of sensing and stimulation is nudging the neurotechnology market size associated with implantable systems toward steady mid-teens expansion.

Brain-computer interfaces (BCIs) are scaling faster, supported by advances in minimally invasive electrode design and cloud-based decoding. The segment's 15.98% projected CAGR makes it the neurotechnology market's fastest mover, attracting partnerships between medical device firms and consumer electronics leaders. Integration with mixed-reality headsets signals potential spill-over into mainstream health monitoring, providing fresh revenue channels beyond clinical neurology. Co-development frameworks are emerging in which hardware, firmware, and data-analytics IP are shared to accelerate iteration cycles.

Chronic pain management commands the largest slice of the neurotechnology market size, accounting for 40.05% of 2025 revenue. Closed-loop spinal-cord systems extend pain relief durability and have allowed many patients to return to work without opioid reliance. Payers view the reduced downstream costs-lower addiction rates and fewer hospitalizations-as justification for coverage, safeguarding the segment's revenue base.

Depression and broader neuro-psychiatric indications are growing at 15.07% through 2031, catalyzed by non-invasive neuro-stimulation modalities that can be administered in outpatient settings. Prefrontal-cerebellar transcranial pulsed-current stimulation improved social functioning in children with autism spectrum disorder during randomized trials. Regulatory momentum is building for psychiatric devices, and ongoing studies aim to formalize dosing protocols, further broadening the addressable population.

Hospitals retained 65.79% of 2025 revenue owing to their expertise in device implantation, programming, and acute monitoring. Leading academic centers leverage integrated care teams that combine neurology, psychiatry, and rehabilitation to optimize outcomes. However, cost pressures and staffing constraints are motivating providers to shift appropriate follow-up to outpatient settings.

Home-care environments exhibit a 14.02% CAGR as compact, connected neurotechnology devices enable clinician oversight without requiring in-person visits. Elderly patients show a rising willingness to adopt remote monitoring when family caregivers are present. Telerehabilitation platforms that pair BCIs with functional electrical stimulation have demonstrated recruitment rates above 80% and retention rates near 88% in stroke populations. These results underscore a growing evidence base supporting decentralized neurological care models.

1. Medtronic
2. Abbott Laboratories
3. Boston Scientific
4. LivaNova
5. Cochlear
6. Nevro
7. NeuroPace
8. Neuronetics
9. Curonix LLC
10. Aleva Neurotherapeutics
11. Synapse Biomedical
12. Synchron
13. Blackrock Neurotech LLC
14. Paradromics Inc.
15. g.tec medical engineering GmbH Austria
16. MindMaze SA
17. Kernel
18. BrainCo Inc.
19. Sonova

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Prevalence of Neurological Disorders
  • 4.2.2 Surging Advancements in Neuroscience and Technology
  • 4.2.3 Growing Demand for Improved Treatment Options
  • 4.2.4 Rising Public & Private Funding for Neurotechnology R&D and Commercialisation
  • 4.2.5 Shift Toward Minimally & Non-invasive Neuro-interventions Enhancing Patient Acceptance
  • 4.2.6 Emergence of Consumer Neurotechnology
• 4.3 Market Restraints
  • 4.3.1 High Up-front Device & Procedure Costs Limiting Adoption Beyond Tier-1 Hospitals
  • 4.3.2 Complex, Multiregional Regulatory Approvals Delaying Market Entry
  • 4.3.3 Reimbursement Gaps & Limited Skilled Workforce in Emerging Economies
  • 4.3.4 Limited Clinical Evidence and Long-Term Data
• 4.4 Regulatory Outlook
• 4.5 Technological Outlook
• 4.6 Porter's Five Forces Analysis
  • 4.6.1 Threat of New Entrants
  • 4.6.2 Bargaining Power of Buyers
  • 4.6.3 Bargaining Power of Suppliers
  • 4.6.4 Threat of Substitutes
  • 4.6.5 Competitive Rivalry

5 Market Size & Growth Forecasts (Value)

• 5.1 By Product
  • 5.1.1 Neuro-stimulation Devices
    • 5.1.1.1 Deep Brain Stimulation (DBS)
    • 5.1.1.2 Spinal Cord Stimulation (SCS)
    • 5.1.1.3 Vagus Nerve Stimulation (VNS)
    • 5.1.1.4 Sacral Nerve Stimulation (SNS)
    • 5.1.1.5 Transcranial Magnetic Stimulation (TMS)
    • 5.1.1.6 Others
  • 5.1.2 Brain-Computer Interfaces
    • 5.1.2.1 Invasive BCI
    • 5.1.2.2 Semi-invasive BCI
    • 5.1.2.3 Non-invasive BCI
  • 5.1.3 Neuro-prosthetics
    • 5.1.3.1 Output Neural Prosthetics
    • 5.1.3.2 Input Neural Prosthetics
  • 5.1.4 Other Products
• 5.2 By Application
  • 5.2.1 Parkinson's Disease
  • 5.2.2 Epilepsy
  • 5.2.3 Alzheimer's and Dementia
  • 5.2.4 Chronic Pain Management
  • 5.2.5 Stroke and Motor Rehabilitation
  • 5.2.6 Depression and Other Neuro-psychiatric Disorders
• 5.3 By End User
  • 5.3.1 Hospitals
  • 5.3.2 Specialty Clinics
  • 5.3.3 Home-care Settings
  • 5.3.4 Research and Academic Institutes
• 5.4 By Geography
  • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
  • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
  • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 Australia
    • 5.4.3.5 South Korea
    • 5.4.3.6 Rest of Asia-Pacific
  • 5.4.4 Middle East and Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle East and Africa
  • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
  • 6.3.1 Medtronic PLC
  • 6.3.2 Abbott Laboratories
  • 6.3.3 Boston Scientific Corporation
  • 6.3.4 LivaNova PLC
  • 6.3.5 Cochlear Limited
  • 6.3.6 Nevro Corp.
  • 6.3.7 NeuroPace Inc.
  • 6.3.8 Neuronetics Inc.
  • 6.3.9 Curonix LLC
  • 6.3.10 Aleva Neurotherapeutics
  • 6.3.11 Synapse Biomedical Inc.
  • 6.3.12 Synchron Inc.
  • 6.3.13 Blackrock Neurotech LLC
  • 6.3.14 Paradromics Inc.
  • 6.3.15 g.tec medical engineering GmbH Austria
  • 6.3.16 MindMaze SA
  • 6.3.17 Kernel
  • 6.3.18 BrainCo Inc.
  • 6.3.19 Sonova

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-need Assessment